Mivacurium: Uses, Dosage, Side Effects & Mechanism | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Mivacurium
Therapeutic Class: Neuromuscular Blocking Agent
Subclass: Non-depolarising Benzylisoquinolinium Muscle Relaxant
Specialty: Anaesthesiology
Schedule (India): Schedule H
Route(s): Intravenous (IV)
Formulations Available in India:
- Mivacurium chloride injection: 2 mg/mL in 5 mL vial (10 mg)
- Mivacurium chloride injection: 2 mg/mL in 10 mL vial (20 mg)
Note: Availability may be limited to select tertiary care centres and teaching hospitals
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶️ Skeletal Muscle Relaxation during General Anaesthesia
| Parameter | Details |
|
Starting dose
|
0.15–0.25 mg/kg IV bolus over 30–60 seconds |
|
Titration
|
Based on neuromuscular monitoring (train-of-four); adjust to surgical requirement |
|
Usual maintenance dose
|
0.1 mg/kg IV supplemental bolus every 15–20 minutes OR continuous infusion 8–10 mcg/kg/min |
|
Maximum dose
|
No fixed maximum; titrate to clinical response |
|
Onset
|
2–3 minutes |
|
Duration of action
|
15–20 minutes (shortest among non-depolarising agents) |
Clinical Notes:
- Short duration makes it suitable for brief procedures or day-case surgery
- Inject slowly over 30–60 seconds to minimize histamine release
- Use peripheral nerve stimulator to guide dosing
- Spontaneous recovery occurs without pharmacological reversal in most cases
▶️ Facilitation of Endotracheal Intubation
| Parameter | Details |
|
Starting dose
|
0.15–0.2 mg/kg IV bolus |
|
Titration
|
Not applicable for intubation dose |
|
Usual maintenance dose
|
As per surgical relaxation dosing |
|
Maximum dose
|
Single intubating dose as stated |
|
Onset
|
2–3 minutes |
Clinical Notes:
- Slower onset than succinylcholine; not ideal for rapid sequence intubation
- Adequate sedation/anaesthesia must be ensured before administration
- Volatile anaesthetics potentiate neuromuscular block; reduce dose accordingly
Secondary Indications — Adults (Off-label, if any)
Not applicable — No established off-label indications documented in Indian practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
▶️ Muscle Relaxation for Surgical Anaesthesia
| Age Group | Starting Dose | Maintenance Dose | Clinical Notes |
|
Neonates (<2 months)
|
Not recommended | Not applicable | Immature plasma cholinesterase activity; unpredictable prolonged paralysis |
|
Infants (2–12 months)
|
0.15–0.2 mg/kg IV bolus | 0.1 mg/kg IV bolus every 10–15 min OR 10–14 mcg/kg/min infusion | Higher infusion rates required; close monitoring essential |
|
Children (1–12 years)
|
0.2–0.25 mg/kg IV bolus | 0.1 mg/kg IV bolus every 10–15 min OR 14–20 mcg/kg/min infusion | Faster recovery than adults; may require higher maintenance doses |
|
Adolescents (≥12 years)
|
0.15–0.25 mg/kg IV bolus | Adult dosing applies | Standard adult pharmacokinetics |
Safety Monitoring:
- Mandatory neuromuscular monitoring (train-of-four or peripheral nerve stimulator)
- Continuous SpO₂ and capnography monitoring
- Heart rate and blood pressure monitoring (histamine release risk)
Minimum Age: Not recommended in neonates (<2 months) due to immature plasma cholinesterase activity. Use in infants (2–12 months) only under paediatric anaesthesiologist supervision.
Secondary Indications — Paediatrics (Off-label, if any)
Not applicable — No established off-label indications in paediatric practice.
RENAL ADJUSTMENT
No dose adjustment required.
Rationale: Mivacurium is metabolised by plasma cholinesterase (butyrylcholinesterase) to inactive metabolites. Elimination is independent of renal function. Safe in patients with renal impairment.
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
|
Mild impairment
|
No adjustment typically required; monitor duration of effect |
|
Moderate impairment
|
Use with caution; plasma cholinesterase may be reduced; prolonged duration possible; titrate using neuromuscular monitoring |
|
Severe impairment
|
Use with extreme caution; significantly prolonged duration expected; avoid repeated dosing without confirmed recovery; consider alternative agents (atracurium, cisatracurium) |
CONTRAINDICATIONS
- Known hypersensitivity to mivacurium chloride or other benzylisoquinolinium compounds
- History of anaphylaxis to any neuromuscular blocking agent
- Known or suspected pseudocholinesterase (butyrylcholinesterase) deficiency — causes severe prolonged paralysis
- Inability to provide adequate mechanical ventilation support
CAUTIONS
- History of asthma or atopy — increased risk of histamine-mediated bronchospasm
- Cardiovascular instability — histamine release may cause hypotension and tachycardia
- Neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome) — extreme sensitivity; avoid or use with extreme caution
- Burns (>24–48 hours post-injury) — resistance may develop; higher doses often required
- Electrolyte abnormalities (hypokalaemia, hypocalcaemia, hypermagnesaemia) — may potentiate blockade
- Elderly patients — may have reduced plasma cholinesterase activity
- Family history of pseudocholinesterase deficiency — screen if possible
- Concurrent use of aminoglycosides or magnesium — potentiate blockade
- Ensure adequate ventilatory support available
PREGNANCY
| Parameter | Details |
|
Risk category
|
No formal Indian category; limited human data |
|
Use in pregnancy
|
May be used when general anaesthesia required; use shortest duration possible |
|
Preferred alternatives
|
Atracurium or cisatracurium may be preferred in obstetric settings due to better safety data |
|
Monitoring
|
Monitor maternal cardiovascular status; fetal heart rate monitoring; assess neonatal respiratory function and muscle tone at delivery |
LACTATION
| Parameter | Details |
|
Compatibility
|
Compatible with breastfeeding |
|
Drug levels in milk
|
Negligible; rapid plasma hydrolysis limits transfer |
|
Preferred alternatives
|
None required for single procedural use |
|
Infant monitoring
|
Not necessary for short procedural use |
|
Resumption
|
May resume breastfeeding once mother is fully conscious and alert |
ELDERLY
- Recommended starting dose: Lower end of range (0.15 mg/kg)
- Titration: Slower; may have reduced plasma cholinesterase activity leading to prolonged duration
- Additional risks: Increased sensitivity; prolonged duration of action; histamine-related hypotension may be more pronounced
- Monitoring: Mandatory neuromuscular monitoring; ensure complete recovery (TOF ratio ≥0.9) before extubation; longer post-operative monitoring recommended
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Aminoglycosides (gentamicin, amikacin, tobramycin)
|
Potentiation of neuromuscular blockade | Avoid if possible; reduce mivacurium dose; monitor closely |
|
Inhalational anaesthetics (isoflurane, sevoflurane, desflurane)
|
Potentiate neuromuscular blockade | Reduce mivacurium dose by 25–40% |
|
Succinylcholine
|
Unpredictable interaction; may synergise or alter duration | Allow recovery from succinylcholine before mivacurium; reduce initial dose |
|
Cholinesterase inhibitors (neostigmine, edrophonium)
|
Inhibit mivacurium metabolism; may paradoxically prolong effect if given prematurely | Use only when spontaneous recovery evident |
|
Anticholinesterases for myasthenia (pyridostigmine)
|
Inhibit mivacurium metabolism | Avoid mivacurium in patients on anticholinesterase therapy |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Magnesium sulphate
|
Enhances neuromuscular blockade | Reduce dose; important in pre-eclampsia/eclampsia |
|
Lithium
|
May prolong neuromuscular blockade | Monitor closely |
|
Phenytoin, Carbamazepine (chronic use)
|
May reduce effect due to enzyme induction | May require higher doses; titrate to effect |
|
Corticosteroids (chronic use)
|
May attenuate neuromuscular response | Monitor effect |
|
Calcium channel blockers
|
May enhance duration of blockade | Monitor neuromuscular function |
|
Clindamycin
|
Potentiate blockade | Monitor closely |
COMMON ADVERSE EFFECTS
- Transient hypotension (histamine release-related; dose and rate dependent)
- Flushing of face, neck, and chest
- Tachycardia
- Bronchospasm (especially in reactive airway disease)
- Injection site reactions
- Prolonged neuromuscular blockade (dose-dependent)
SERIOUS ADVERSE EFFECTS
- Severe prolonged paralysis — in pseudocholinesterase deficiency; may last several hours; requires extended mechanical ventilation
- Anaphylaxis/Anaphylactoid reactions — rare but potentially fatal; immediate discontinuation and resuscitation required
- Severe bronchospasm and laryngospasm — especially in asthmatics
- Cardiovascular collapse — from severe histamine-mediated vasodilation (usually with rapid high-dose bolus)
- Respiratory arrest — if ventilatory support inadequate
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline
|
Neuromuscular function; cardiovascular status; allergy history; family history of anaesthetic complications |
|
During use
|
Continuous neuromuscular monitoring (TOF/peripheral nerve stimulator); heart rate; BP; SpO₂; ETCO₂; ECG |
|
Before extubation
|
Ensure TOF ratio ≥0.9; clinical assessment (sustained head lift ≥5 seconds, adequate grip strength) |
|
In hepatic dysfunction
|
Consider plasma cholinesterase activity measurement if available |
BRANDS AVAILABLE IN INDIA
- Mivacron (limited availability; may be available via hospital import or select institutional supply)
Note: Availability in India is restricted; may not be stocked in all centres. Confirm availability before planning use.
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Mivacurium 10 mg (5 mL) vial | ₹500–₹850 |
- Not under NPPA/NLEM price control
- Limited availability; pricing may vary based on import and institutional procurement
- Government supply availability inconsistent
CLINICAL PEARLS
- Shortest-acting non-depolarising agent — ideal for short procedures, day-case surgery, and situations where rapid spontaneous recovery is desirable without pharmacological reversal
- Screen for pseudocholinesterase deficiency — family history or previous anaesthetic complications should prompt caution; prolonged paralysis (hours) may occur in deficient patients
- Histamine release is dose and rate dependent — always inject slowly over 30–60 seconds; avoid bolus doses >0.2 mg/kg to minimize hypotension
- Not suitable for ICU paralysis — very short duration makes continuous infusion impractical; prefer vecuronium, atracurium, or cisatracurium for ICU use
- Recovery usually spontaneous — pharmacological reversal with neostigmine often unnecessary; if used, give only when TOF shows ≥2 twitches
- Limited availability in India — confirm stock availability before surgical planning; alternative agents should be available as backup
TAGS
mivacurium; neuromuscular blocking agent; NMBA; benzylisoquinolinium; short-acting; anaesthesia; muscle relaxant; histamine release; pseudocholinesterase; day-case surgery; Schedule H
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO-approved prescribing information
- Indian Pharmacopoeia
- National Formulary of India
- AIIMS Anaesthesia protocols
- Goodman & Gilman’s Pharmacological Basis of Therapeutics
- API Textbook of Medicine
- Indian specialist anaesthesia practice
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.